Leading the Way in Life Science Technologies

GEN Exclusives

More »

GEN News Highlights

More »
Oct 24, 2006

Separate Manufacturing Deals Inked at Cleveland BioLabs and Viron Therapeutics

  • Cleveland BioLabs (CBLI) and SynCo Bio Partners completed the transfer of technology in their joint effort to produce CBLI's lead product, Protectan CBLB502, and have signed an agreement to produce sufficient amounts for clinical trials and the commercial market.

    SynCo will work with CBLI to develop the manufacturing process, as well as manufacture CBLB502 for Phase I trials and commercial release.

    Viron Therapeutics signed an agreement with Diosynth Biotechnology for process development, scale-up, and clinical manufacturing of VT-111. Under the agreement, Diosynth Biotechnology will support the process improvement, process development, and clinical product manufacturing.



Be sure to take the GEN Poll

CRISPR Patent Controversy

Do you think recently released email from a former Broad Institute scientist to Jennifer Doudna will expedite a final legal decision on who owns the CRISPR patent?

More »